Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by J. Randolph Hecht, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cardiff Oncology
- Links
- Sign up for this study
- ID
- NCT06106308
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 90 study participants
- Last Updated